Lobe Sciences is a life sciences company focused on psychedelic medicines and specializing in the treatment of PTSD and mTBI through microdosing methodology. Through the acquisition of Eleusian Biosciences, the company is engaged in research and development of using psychedelic compounds and innovative devices and delivery mechanisms to improve mental health and wellness. They have a strong IP platform with several pending patents for drug compounds and delivery devices.
Lobe listed on the CSE through a reverse takeover of Green Star Biosciences and is currently trading under the symbol 'LOBE.' The company also trades under the symbol “GTSIF” on the OTCQX.
- 5 patent applications, including three on novel drug compounds, focusing on unique formulations of NAC combined with psilocybin or MDMA, and two on unique delivery devices and delivery methods.
- Developed proof-of-concept prototype of its proprietary nasal mist device.
- Patent pending on drug formulation designed to promote memory odour imprint pairing.
- Developing virtual reality headset combined with nasal mist device in order establish guided meditations and assisted therapy sessions in tandem with micro dosing treatment.
Phillip J. Young, Chief Executive Officer & Director
Maghsoud Dariani, Chief Science Officer
Dr. Mark A. Geyer, PHD, Science Advisor
Benjamin Kelmendi, MD, Scientific Advisor